Analysis: a bivalent vaccine has been approved and research is being carried out into possible pan-coronavirus vaccines
When the autumn booster programme begins next month, many people are likely to receive Moderna’s new bivalent vaccine, designed to protect against the original Covid strain and the more transmissible Omicron variant. As Covid continues to evolve, so will vaccination strategies. Here we look at some of the developments in the pipeline.
